

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malaria | D008288 | EFO_0001068 | B54 | 3 | 6 | — | — | — | 9 |
| Falciparum malaria | D016778 | EFO_0007444 | B50 | 2 | 1 | — | — | — | 3 |
| Vivax malaria | D016780 | EFO_0007445 | B51 | — | 1 | — | — | — | 1 |
| Drug common name | CIPARGAMIN |
| INN | cipargamin |
| Description | Cipargamin (NITD609, KAE609) is an experimental synthetic antimalarial drug belonging to the spiroindolone class. The compound was developed at the Novartis Institute for Tropical Diseases in Singapore, through a collaboration with the Genomics Institute of the Novartis Research Foundation (GNF), the Biomedical Primate Research Centre and the Swiss Tropical Institute.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | C[C@H]1Cc2c([nH]c3cc(Cl)c(F)cc23)[C@@]2(N1)C(=O)Nc1ccc(Cl)cc12 |
| PDB | — |
| CAS-ID | 1193314-23-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1082723 |
| ChEBI ID | — |
| PubChem CID | 44469321 |
| DrugBank | DB12306 |
| UNII ID | Z7Q4FWA04P (ChemIDplus, GSRS) |
